BIO leader hits proposal for drug price regulation

BIO leader hits proposal for drug price regulation The Cambridge-based chairman of the nation’s largest biotech organization is strongly opposing any federal controls in drug pricing if a prescription drug component is added to Medicare. “It’s price controls or innovation; you can’t have both,” said Richard Pops, who recently was elected to head the board […]

Biotech industry in survival mode

Biotech industry in survival mode Restructuring, retrenching and reinventing themselves, Bay Area biotechnology firms are adapting to weather the economic downturn. … “We’ve noticed (biotech companies) will abandon one or two research products and in the process may have discovered something of more use, readjusting their core competency to find something marketable today, rather than […]

No simple generic answer

No simple generic answer Unlike pills and capsules that are brewed from a mixture of chemicals, injectable therapies like hormones and genetically engineered proteins are not covered by the Hatch-Waxman Act, the 1984 law that laid the foundation for the nation’s generic drug industry. That has left brand-name biotech manufacturers with the hope of monopolies […]

Antibacterials: a dying trade

Antibacterials: a dying trade : Despite strong worldwide demand for effective antibacterial products, sustaining growth within this segment will become a challenging task for major pharmaceutical companies. Currently only six marketed drugs have sales of greater than $1 billion and by 2011, 12 out of 29 key products will face patent expiry. A relatively sparse […]

Can Your Genomics Work Contribute to Biodefense

Can Your Genomics Work Contribute to Biodefense Three years ago, Luis Villarreal, a virologist at the University of California, Irvine, came up with the idea of using in vitro gene activation by PCR to study the proteome of a virus in hopes of developing a high-throughput platform for identifying new vaccines. Villarreal and his collaborators […]

Biogen/Idec: still a matter of size

Biogen/Idec: still a matter of size The merger of Biogen and Idec Pharmaceuticals, announced June 23, is likely to help the two relatively isolated companies increase presence in their disease areas. The annual R&D budget for the new pharmaceutical entity, to be called Biogen Idec Inc, will be $500 million, according to company reports.